Study says using hep C drugs early will save healthcare dollars; Pfizer's Chantix found to initially help women more than men stop smoking;

@FiercePharma: Something's got to give in India's pharma policy contradictions. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: AmerisourceBergen looks for compound interest with its $2.5B deal to buy PharMEDium. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Investors cheer as Arena forces out CEO and cofounder. More | Follow @CarlyHFierce

> A new study says that treating 5% of all hepatitis C patients with the latest drugs would be more cost-effective at reducing infections and health care costs than the current approach of waiting for the disease to advance before treatment. Story

> An FDA official is raising questions about the value of priority review vouchers, which companies now buy from each other for hundreds of millions of dollars in an effort to jump up in line to get drugs approved. Story

> Sanofi ($SNY) has launched a generic of its own rheumatoid arthritis drug, Arava. Report

> A new study says that Pfizer's ($PFE) smoking cessation drug Chantix is more effective in women than in men in early months of use and just as effective for both genders after a year. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Report | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: Director of says local coverage decisions are varying by locality. Not all geographies reimburse Dx tests the same way. | Follow @VarunSaxena2

@EmilyWFierce: Sold on diabetes tech, Joslin tests mobile app for Type 1 patients. FiercePharmaMarketing story | Follow @EmilyWFierce

> OptiNose raises up to $30M to get drug-device combo through FDA. Story

> Stratatech nabs $247M BARDA contract for skin tissue device. Article

Biotech News

@FierceBiotech: Take the poll: Has the biotech boom come to an end? More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, U.K. More | Follow @JohnCFierce

> Quartet closes an up-sized A round with a novel approach to pain. News

> Aclaris limps out to a $55M IPO as biotech falters on Wall Street. Report

> Advaxis offers a tardy defense after FDA puts cancer vaccine on hold. Article

Biotech Research News

> Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's. More

> Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance. Report

> Penn team shines a light on blood disorder. Item

> UCSC team reveals key structural component in telomerase enzyme. Story

> NIH researchers' new mouse model points to a gene therapy for eye disease. Article

Diagnostics News

> Myriad inks coverage deal for prostate cancer test. Item

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Report

> Cancer Genetics makes strides in $14M deal for Response Genetics. More

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Article

> Illumina expands in China with cancer Dx deal. Story

Pharma Marketing News

> Can Daklinza profit from a set of niche hep C uses? BMS may soon find out. Item

> Bristol-Myers shells out $14.7M in China bribery settlement. More

> British docs weigh in on pharma, and it's no better than most U.S. opinions. Report

> The data difference? Publicis adds data practice to sharpen healthcare media buying and planning. Story

> Glaxo OTC chief: When it comes to consumer health, pharma has the edge. Article

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.